Clinical Trial Update: Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL [Phase 2]

View source ↗

Summary

An exploratory Phase 2 clinical trial evaluating Orelabrutinib for early-stage, untreated marginal zone lymphoma is currently recruiting in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Marginal Zone Lymphoma | Phase 2 | Status: RECRUITING